NewAmsterdam Pharma Company N.V. (NAMS)
(Delayed Data from NSDQ)
$23.62 USD
+1.89 (8.70%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $23.64 +0.02 (0.08%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NAMS 23.62 +1.89(8.70%)
Will NAMS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NAMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NAMS
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates
Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know
NAMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates
Other News for NAMS
Decoding NewAmsterdam Pharma Co NV (NAMS): A Strategic SWOT Insight
NewAmsterdam Pharma reports Q2 results
NewAmsterdam Pharma Co NV Reports Q2 2025 Earnings: EPS of -$0. ...
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results | ...
NewAmsterdam Pharma reports Q2 revenue $19.145M vs $2.279M last year